Latest and Past News
-
Medical, nursing and patient groups unite to contest INESSS report on Hemlibra
Montreal, March 29, 2021 – Medical and patient groups in Quebec and across Canada have united in their rejection of the recommendation by Quebec’s health...
-
Best Medicines Coalition submission on high-cost drugs for rare diseases
The Best Medicines Coalition (BMC) is a national alliance of patient organizations, together representing millions of patients, with a shared goal of equitable, timely and...
-
CHS replies to Quebec’s INESSS following its shocking report on the funding of Hemlibra
The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...
-
Fitusiran trial restarts with new controls
BRUSSELS – During the European Association for Haemophilia and Allied Disorders (EAHAD) virtual congress session on the latest clinical trial, Dr. Shauna Anderson, representing Sanofi,...
-
Community awaits decisions on access to Hemlibra
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...
-
Results from a CHS/Novo Nordisk Psychosocial Research Program project now published
In 2018, Jennifer King, social worker at the Saskatchewan Health Authority in Saskatoon, was awarded a grant through the CHS/Novo Nordisk Psychosocial Research Program for...
-
FAQs – COVID-19 vaccine and bleeding disorders
The Association of Hemophilia Clinic Directors of Canada (AHCDC) has issued a message to address the most frequent questions asked with regards to the COVID-19...
-
COVID-19 vaccination guidance for people with bleeding disorders
CLICK HERE to read the joint guidance notice from the World Federation of Hemophilia (WFH), European Association for Haemophilia and Allied Disorders (EAHAD), European Haemophilia Consortium...
-
FDA puts uniQure’s gene therapy clinical programme, HOPE-B, on hold following submission of a safety report
December 21, 2020 – The European Haemophilia Consortium (EHC) has learned that uniQure announced that its haemophilia B gene therapy programme, including the pivotal, phase...
-
Announcement of a clinical trial for Vioxx for people with hemophilia
(…) The pain drug became synonymous with pharmaceutical risk more than 15 years ago when studies revealed that it roughly doubled patients’ risk of heart...
-
CHS James Kreppner Memorial Scholarship and Bursary Program
Information including the criteria and application forms for the CHS James Kreppner Memorial Scholarship and Bursary Program is available on the CHS website at www.hemophilia.ca/james-kreppner-memorial-scholarship-and-bursary-program....
-
European Haemophilia Consortium New Products Review
Read the latest research news about innovative coagulation products – factor replacement products, non-factor therapies and gene therapies – in the European Haemophilia Consortium New...
-
Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
-
A Patient Videoconference on Inhibitors & New Novel Therapies – Answering Your Questions!
On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a...